Hemophilia Market Size, Share, Trends, Growth and Forecast 2032

Hemophilia Market Insights

Zion Market Research has published a report on the global Hemophilia Market, estimating its value at USD 13.01 Billion in 2023, with projections indicating that it will reach USD 23.08 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 6.58% over the forecast period 2024-2032.

The report explores the factors fueling market growth, the hitches that could hamper this expansion, and the opportunities that may arise in the Hemophilia industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period. The report offers historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on value (USD Billion).

Request Free Sample

Hemophilia Market: Overview

Hemophilia is a most common as well as serious genetic hemorrhagic disease. There are two kinds of hemophilia, namely, hemophilia A and hemophilia B. Moreover, they are caused due to factors VIII protein deficiency as well IX protein deficiency and is impacted due to continuous & excessive bleeding post minor trauma. Reportedly, acquired hemophilia can be present in an individual right from childbirth and can be cured after apt treatment. According to NCBI, hemophilia was the word first introduced by Johann Schonlein in his dissertation at Zurich University. For the record, Dr. Nasse first published genetic description of hemophilia in Nasse’s law stating the transmission of hemophilia from unaffected mothers to the sons.

Furthermore, hemophilia has been treated with prophylactic therapy with the latter helping in prevention of bleeding as well as reducing complications resulting due to hemophilia. With onset of gene therapy and with other treatments imitating sustained coagulation factor replacement, the hemophilia market is likely to gain traction over the years ahead.

Request Free Sample

Hemophilia Market:? Growth Drivers

Focus on new drug development along with favorable government policies for curbing the disease is likely to prompt the expansion of hemophilia market over the forecast timespan. In addition to this, rise in the awareness about rare disease such as hemophilia and growing efforts made by both private & public healthcare research organizations to produce drugs for effectively treating the disorder will impel the business growth. Apparently, huge allocation of funds by giant pharma firms in research & development to find new ways of treating the genetic disease will proliferate the expansion of the hemophilia industry over the forecast timespan.

Furthermore, enhanced distribution networking facility of the mammoth players in the pharmaceutical industry will culminate into huge market demand over the forecasting timeframe. As per Centers for Disease Control and Prevention (CDC), nearly four hundred babies are born with hemophilia in the U.S. each year and this will boost the demand for hemophilia treatment in the country, thereby driving the market trends.

Hemophilia Market: Report Scope

Hemophilia Market: Regional Insights

North America To Form Strong Base For Market Growth By 2032

The regional market dominance during the estimated timeframe can be attributed to increase in the number of hemophilia cases in the countries like the U.S. In addition to this, rise in the use of prophylaxis therapy for hemophilia in the region will promulgate the business growth in the sub-continent over the forecast timespan. Presence of behemoth pharmaceutical firms as well as healthcare service providers in the countries such as Canada and the U.S. are expected to boost the regional market trends.

Hemophilia Market: Competitive Space

Key participants profiled in the study are -

• Novo Nordisk
• CSL Behring
• BioMarin Pharmaceutical, Inc.
• Roche (Chugai Pharmaceutical Co.)
• Pfizer, Inc.
• Bayer AG
• Sanofi (Genzyme Corporation);Kedrion
• Takeda Pharmaceutical (Shire Plc.).

The global hemophilia market is segmented as follows:

By disease type:

• Hemophilia A
• Hemophilia B
• Others

By therapy:

• Replacement Therapy
• Gene Therapy
• Others (Immune Tolerance Induction Therapy etc.)

By product type:

• Recombinant Coagulation Factor Concentrates
• Plasma-derived Coagulation Factor Concentrates
• Others (Desmopressin etc.)

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa